EUVIMEDSkopri EUVIMED
Crossref

AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway

Jinsi Chen, Jia Zhang, Wei Tian, Chao Ge, Yuting Su, Jinjun Li, Hua Tian iD

Molecular Carcinogenesis · 2023-06 · 62 (6) · 833-844

DOI: 10.1002/mc.23527 ↗

At a glance

Journal article in Molecular Carcinogenesis, published online on 2023-03-15. Written by Jinsi Chen and 6 co-authors. Institution: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Sha…. Major MEDLINE topics: Carcinoma, Hepatocellular, Ferroptosis, Liver Neoplasms. Cited 53 times so far (Crossref); 31 references. Funded by: Natural Science Foundation of Shanghai, National Natural Science Foundation of China.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

AKR1C3 is frequently overexpressed and it is a validated therapeutic target in various tumors including hepatocellular carcinoma (HCC). Our previous study showed that AKR1C3 facilitated HCC proliferation and metastasis by forming a positive feedback loop of AKR1C3‐NF‐κB‐STAT3. Ferroptosis is a form of iron‐dependent cell death driven by iron‐dependent accumulation of lipid reactive oxygen species and plays an important role in tumor suppression. However, little is known about the role of AKR1C3 in ferroptosis susceptibility. In this study, we found that knockdown of AKR1C3 potently enhanced the sensitivity of HCC cells to ferroptosis inducers both in vitro and in vivo. Overexpression of AKR1C3 protected against ferroptosis in HCC cells. Mechanistically, AKR1C3 regulated ferroptosis through YAP/SLC7A11 signaling in HCC. AKR1C3 knockdown led to a decrease in YAP nuclear translocation, resulted in the inhibition of cystine transporter SLC7A11, and a subsequent increase in the intracellular levels of ferrous iron and ultimately ferroptosis. Moreover, we found that the combination of AKR1C3 and SLC7A11 was a strong predictor of poor prognosis in HCC. Collectively, these findings identify a novel role of AKR1C3 in ferroptosis, and highlighting a candidate therapeutic target to potentially improve the effect of ferroptosis‐based antitumor therapy.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularFerroptosisLiver NeoplasmsHumansSignal TransductionIronAldo-Keto Reductase Family 1 Member C3Amino Acid Transport System y+

Author keywords

AKR1C3SLC7A11YAPferroptosishepatocellular carcinoma

Substances

IronAKR1C3 protein, humanAldo-Keto Reductase Family 1 Member C3SLC7A11 protein, humanAmino Acid Transport System y+

Authors and institutions

  • State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID profiles: Hua Tian

Funding

  • Natural Science Foundation of Shanghai
  • National Natural Science Foundation of China

Cite

APA

Chen, J., Zhang, J., Tian, W., Ge, C., Su, Y., Li, J., & Tian, H. (2023). AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway. Molecular Carcinogenesis, 62(6), 833-844. https://doi.org/10.1002/mc.23527

Vancouver

Chen J, Zhang J, Tian W, Ge C, Su Y, Li J, et al. AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway. Molecular Carcinogenesis. 2023;62(6):833-844. doi:10.1002/mc.23527

BibTeX
@article{Chen2023,
  author = {Chen, Jinsi and Zhang, Jia and Tian, Wei and Ge, Chao and Su, Yuting and Li, Jinjun and Tian, Hua},
  title = {AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway},
  journal = {Molecular Carcinogenesis},
  year = {2023},
  volume = {62},
  number = {6},
  pages = {833--844},
  doi = {10.1002/mc.23527}
}
Start for free →